Drug intelligence / Profile preview

oxycodone DETERx

Development stage
Phase 4
Lead developer
Collegium Pharmaceutical
Modality
Small Molecules
Administration
Oral, Gastrostomy, Nasogastric
01

Overview

Oxycodone DETERx is an extended-release, abuse-deterrent formulation of oxycodone designed to retain its extended-release properties even after physical manipulation such as crushing or chewing. It's marketed under the brand name Xtampza ER and uses a novel microsphere-in-capsule technology. The formulation consists of oxycodone base combined with fatty acids and waxes to form hydrophobic, waxy microspheres. This unique composition makes it difficult to extract the active ingredient for abuse while allowing alternative administration methods for patients who have difficulty swallowing. ## Pharmacokinetics and Abuse Deterrence Oxycodone DETERx maintains its extended-release properties even when manipulated. Studies have shown that chewed and intact oxycodone DETERx are bioequivalent, unlike crushed immediate-release oxycodone which yields higher peak plasma concentrations[1][6]. This is significant because: 1. The maximum effect (Emax) for drug liking was significantly lower for chewed and intact oxycodone DETERx compared to crushed immediate-release oxycodone[1][6] 2. The time to Emax was significantly longer for oxycodone DETERx formulations[1][6] 3. Scores for "feeling high" were lower for oxycodone DETERx compared to immediate-release oxycodone[1][6] These properties make oxycodone DETERx less attractive for abuse via oral routes, which often serve as a gateway to more dangerous routes of administration. ## Clinical Applications Oxycodone DETERx is indicated for the management of pain severe enough to require daily, around-the-clock opioid treatment for an extended period, when alternative treatment options are inadequate[3][8]. In clinical trials involving patients with chronic lower back pain, oxycodone DETERx demonstrated significant pain reduction compared to placebo[3]. A key advantage of this formulation is its versatility in administration. Unlike most extended-release opioids, oxycodone DETERx can be: - Administered by sprinkling onto soft food - Delivered via gastrostomy tube - Delivered via nasogastric tube[1] This provides important options for patients with difficulty swallowing or those requiring alternative administration routes.

Brand names
Xtampza ER
Other names
oxycodone extended-releaseoxycodone ERoxycodone extended-release capsules
02

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on oxycodone DETERx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxycodone DETERx.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call